HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial
- Authors: Crabbe R, Cuypers L, Kerremans L, Libin P, Snoeck J, Van Dooren S, Vandamme AM, Vuagniaux G
- Publication Year: 2016
- Journal: Infection Genetics and Evolution
- Link: https://www.sciencedirect.com/science/article/pii/S156713481630274X?via%3Dihub
Major advances have revolutionized the HCV antiviral treatment field, with interferon-free combinations of direct-acting antivirals (DAAs) resulting into success rates of >90% for all HCV genotypes. Nevertheless, viral eradication at a global level stills remains challenging, stimulating the continued search for new affordable pan-genotypic drugs. To overcome selection of drug resistant variants, targeting host proteins […]
Read More